Phase I/IIa study of intravesical administration of 2-methyl-3-butenyl-1-pyrophosphate-stimulated gamma delta T cells in patients with non-invasive bladder cancer.
Not Applicable
- Conditions
- on-invasive bladder cancer
- Registration Number
- JPRN-UMIN000010942
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1) No hypercalcemia that require medication, No C-reactive protein with an infectious disease that requires medication, No active infection with hepatitis virus or HIV, No current treatment with steroids and immunosuppressive drugs, No poorly controlled DM or heart failure or arrhythmia, No autoimmune disease and interstitial pneumonia, No other malignancy, No bone of organ transplant recipient, Not pregnant nor nursing, No mental disorder 2) Other patients judged to be ineligible by the attending investigators were also excluded from the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and efficacy: Adverts events are accessed by CTCAE ver.4.0. Efficacy is accessed by cystoscopy examination and immunohistochemical staining of the bladder cancer.
- Secondary Outcome Measures
Name Time Method